Background: Monopolar radiofrequency devices for facial skin tightening offer a promising non-invasive approach that targets the deep dermis to prompt immediate collagen contraction and subsequent remodeling.However, non-clinical evidence supporting the efficacy and mechanisms of action of these treatments remains limited, despite their increasing use. This study aimed to evaluate the effectiveness and safety of a dualfrequency non-invasive monopolar radiofrequency (NMRF) device using a porcine model, directly comparing a conventional 6.78 MHz setting with a dual-frequency (6.78 + 2 MHz) mode. Methods: Female porcine subjects were treated using an innovative NMRF device (XERF; Cynosure Lutronic Inc.). Efficacy was assessed histologically for up to 1 month. Safety was evaluated through thermal skinsurface monitoring and standard assessments. Results: When compared with 6.78 MHz alone, the dual-frequency (6.78 + 2 MHz) mode produced greater immediate thickening and shortening of deep dermal collagen bundles and more prominent remodeling of subcutaneous fibrous septa. At 1 month, the dual-frequency treatment yielded larger increases in dermal collagen density, more regular bundle alignment, and higher elastin signals. Surface temperature remained below 43ºC, and no tissue damage was observed following NMRF treatment. Conclusion Our research strongly indicates that immediate tissue contraction occurs following treatment and that dual-frequency application results in more substantial collagen reconstruction. In the long term, NMRF stimulates the production of new collagen and elastin. The dual-frequency mode enhances these effects, supporting its use in effective and safe skin tightening and rejuvenation.

Human pluripotent stem cells (hPSCs) can be used to investigate hematopoietic development and have the potential to advance cell-based therapies and to facilitate developmental biology studies. However, efficient ex vivo differentiation into hematopoietic lineages, including red blood cells (RBCs) of the erythroid lineage and immune cells such as macrophages of the myeloid lineage, is hampered by the need for precise temporal regulation of cytokines and growth factors.In this study, we developed an optimized protocol for hematopoietic lineage specification from hPSCs by fine-tuning the temporal dynamics of cytokine and growth factor applications. Prolonged mesodermal specification in the absence of hemogenic cytokines significantly enhanced the generation of hematopoietic progenitors (CD34＋ CD45＋ ) with robust functional potential. Early administration of interleukin (IL)-3 during hematopoietic specification promoted progenitor expansion and maturation. Supplementation of bone morphogenetic protein 4 at the hematopoietic maturation stage enhanced the differentiation efficiency and preferentially drove myeloid lineage commitment toward macrophages at the expense of erythroid differentiation. The timing of erythropoietin administration was important in erythroid lineage commitment, and delayed treatment (day 10) enhanced erythroblast expansion and RBC production. By contrast, the timing of IL-6, GM-CSF, and M-CSF exposure did not significantly affect macrophage differentiation efficiency, suggesting that myeloid lineage specification follows a default pathway under optimized differentiation conditions. These findings suggest a refined, time-controlled strategy for directing hematopoietic differentiation from hPSCs, and provide insight into therapeutic blood cell production, regenerative medicine, and ex vivo modeling of hematopoietic disorders.

Porcine epidemic diarrhea virus (PEDV) has posed significant financial threats to the domestic pig industry over the last three decades in South Korea. PEDV infection will mostly result in endemic persistence in the affected farrow-to-finish (FTF) herds, leading to endemic porcine epidemic diarrhea (PED) followed by year-round recurrent outbreaks. This review aims to encourage collaboration among swine producers, veterinarians, and researchers to offer answers that strengthen our understanding of PEDV in efforts to prevent and control endemic PED and to prepare for the next epidemics or pandemics. We found that collaboratively implementing a PED risk assessment and customized four-pillar-based control measures is vital to interrupt the chain of endemic PED in affected herds: the former can identify on-farm risk factors while the latter aims to compensate for or improve weaknesses via herd immunity stabilization and virus elimination. Under endemic PED, long-term virus survival in slurry and asymptomatically infected gilts (“Trojan Pigs”) that can transmit the virus to farrowing houses are key challenges for PEDV eradication in FTF farms and highlight the necessity for active monitoring and surveillance of the virus in herds and their environments. This paper underlines the current knowledge of molecular epidemiology and commercially available vaccines, as well as the risk assessment and customized strategies to control PEDV. The intervention measures for stabilizing herd immunity and eliminating virus circulation may be the cornerstone of establishing regional or national PED eradication programs.

Huntington's disease (HD) is a late-onset and progressive neurodegenerative disorder that is caused by aggregation of mutant huntingtin protein which contains expanded-polyglutamine. The molecular chaperones modulate the aggregation in early stage and known for the most potent protector of neurodegeneration in animal models of HD. Over the past decades, a number of studies have demonstrated molecular chaperones alleviate the pathogenic symptoms by polyQ-mediated toxicity. Moreover, chaperone-inducible drugs and anti-aggregation drugs have beneficial effects on symptoms of disease. Here, we focus on the function of molecular chaperone in animal models of HD, and review the recent therapeutic approaches to modulate expression and turn-over of molecular chaperone and to develop anti-aggregation drugs.
Huntington Disease* ; Models, Animal ; Molecular Chaperones ; Neurodegenerative Diseases